Background: Molecular imaging of immune cells might be a potential tool for response prediction, treatment evaluation and patient selection in inflammatory diseases as well as oncology. 
. Many immunotherapeutics are based on the activation of effector T-cells. Therefore, targeting these activated Tcells specifically with a radiolabeled imaging probe, might be a potential molecular imaging strategy in this context. The interleukin-2 (IL2) receptor, consisting of three subunits CD25, CD122 and CD132, is mainly expressed by these activated effector T-cells and by a subpopulation of regulatory T-cells (Malek & Castro, 2010) . Molecular imaging of IL2 receptors using radiolabeled recombinant human IL2 could be a strategy to track activated T-cells expressing the IL2 receptor. In the past, IL2 receptors have been imaged using single photon emission computed tomography (SPECT) with technetium-99 m ( 99m Tc) or iodine-123 ( 123 I) labeled IL2 analogues. Imaging could detect T-cell infiltration in patients with melanoma, carcinoma and various inflammatory disorders (Signore et al., 2004; Loose et al., 2008; Signore et al., 2003; D'Alessandria et al., 2010; Hubalewska-Dydejczyk et al., 2009 ). However, SPECT has a low spatial resolution and sensitivity, which makes it difficult to detect small lesions or lesions with low to moderate T-cell infiltration. Moreover, absolute quantification of the imaging signal is difficult with SPECT. Furthermore, for the purpose of early response prediction is it important to not only to detect T-cells, but also to be able to quantify the signal. human and murine T-cells as well as migration of these T-cells to distant sites of inflammation (Di Gialleonardo et al., 2012a) . In immune competent rats, the accumulation of [ 18 F]FB-IL2 correlated with the number of injected activated CD25-positive human T-cells (Di Gialleonardo et al., 2012b) . To bring this interesting PET tracer to the clinic, the production method needed to be adapted to suit strict regulations for production of radiopharmaceuticals. National guidelines in different EU countries impose to produce radiopharmaceuticals according to Good Manufacturing Practices (GMP) guidelines (Bormans et al., 2017) . With these guidelines the quality of the radiopharmaceutical can be warranted, resulting in a radiopharmaceutical suitable for human use. Not only a robust and consistent production process is needed, but also final formulation must be of consistent quality and composition. Furthermore, production of the radiopharmaceutical suitable for human use implies the use of higher amounts of radioactivity and as a result protection of the operator from exposure to radiation is required. It requires that the partly manual production method developed and used in a research and development (R&D) setting is converted into a fully automated GMP compliant production method. Moreover, the final formulation needs to be safe for human use and additionally suitable purification and sterilization methods are required.
Guided by the phases of the development path of radiopharmaceuticals ( Fig. 1 ) we here describe the challenges encountered during the translation to the GMP environment. Solutions for the encountered problems and the consequent changes in the production method are described. These modifications have resulted in a GMP compliant production process for the radiopharmaceutical suitable for firstin-human clinical use. 
Methods

Preclinical development
The production method of [ 18 F]FB-IL2 developed for preclinical studies has been described by Di Gialleonardo et al. (Di Gialleonardo et al., 2012b) . In short, this production method consists of four steps as depicted in Fig. 2 (HPLC) using an Elite LaChrom Hitachi L-7100 pump system with an Econosphere C18-column (10 μm, 250 mm × 10 mm) equipped with both ultraviolet (UV) detection (Elite LaChrom VWR L-2400 UV detector set at 254 nm; Hitachi) and a Bicron radioactivity monitor. Gradient elution was performed using a mixture of 0.1% aqueous trifluoroacetic acid and 0.1% trifluoroacetic acid (TFA) in ethanol. The product was collected from HPLC in approximately 55% ethanol in water. Thereafter, the product . Then, a solution of 20 mg O-(N-succinimidyl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TSTU, Sigma-Aldrich) in anhydrous MeCN (0.5 mL) was added, and the mixture was heated at 85°C for 5 min. The mixture was cooled, diluted with 1 M HCl (0.4 mL) and purified by HPLC (Symmetry Shield RP8 5 μm, 7.8 × 300 mm, 40% MeCN in water, flow 4 mL/min). The radioactive product with a retention time of approximately 8 min was collected into a 25 mL sterile vial (Mallinckrodt) via a sterilization filter (Millex-LG filter, 25 mm diameter, 0.2 μm pore size, polytetrafluoroethylene membrane, Millipore). Quality control (QC) was performed, including determination of appearance, yield and radiochemical purity, as described below. 10 min. Thereafter, the reactor was cooled to room temperature and the reaction mixture was diluted with 1 ml sodium chloride 0.9% (Braun) containing 22 μL 25% phosphoric acid (H 3 PO 4 , Sigma-Aldrich) and 48 μL 10% sodium dodecyl sulfate (SDS). After this, the reaction mixture was passed through a tC2 Sep-Pak cartridge (Waters). The reactor and the cartridge were washed three times with 2 mL 50% aqueous ethanol containing 23 μL 25% H 3 PO 4 . The cartridge was then washed with 1 mL of water for injection and thereafter, [ 18 F]FB-IL2 was eluted from the cartridge with 1 mL 100% ethanol containing 5 μL 0.25% H 3 PO 4 and transferred via a sterilization filter (Millex-GV filter, 13 mm diameter, 0.22 μm pore size, Millipore) to a glass vial, European Pharmacopoeia (Ph. Eur.) type I, sterile and pyrogen free, covered with a bromobutyl rubber stopper, sealed with a flip-off aluminum cap (Mallinckrodt/ ABX) containing 6.5 mL of 5% glucose, 0.1% SDS and 0.5% human serum albumin (HSA, Albuman, Sanquin) solution. The cartridge and sterilization filter are rinsed with 3.5 mL 5% glucose and 0.1% SDS solution, which is also collected in the sterile vial. After 14 days at 25°C, the clarity of the medium is visually inspected. In case the medium is not clear the sample is tested for the bacterial strain present. Kryptofix is determined by the kryptofix spot test using silica thin-layer chromatography (TLC) strips treated with an aqueous iodoplatinate solution. Discoloration of the strip will be compared with a 25 mg/ml kryptofix reference sample. Radionuclide purity is determined with a germanium detector. Radionuclide identity is determined for the gamma spectrum emitted by the drug product. The half-life is determined by measuring the radioactive decay over time. Specific for this tracer was the use of ultra-performance liquid chromatography (UPLC) for analysis of (radio) chemical purity, radiochemical identity and molar activity. For this, a Waters Acquity H-Class system and a BEH Shield RP18 column (1.7 μm; 3.0 mm × 50 mm) was used, equipped with both an UV detector (operated at 225 and 280 nm) and a radioactivity detector (Berthold FlowStar LB513, Mx50-6 flow cell). Gradient elution with a mixture of 0.1% aqueous TFA in ultrapure water (solvent A) and 0.1% TFA in mass spectrometry-grade acetonitrile (solvent B) was performed at a flow of 0.8 mL/min. The following gradient profile was used: 0-1 min 5% B, 1-4 min 30% B, 4-6 min 50% B, 6-8 min 50% B, 8-10 min 70% B, 10-11 min 5% B. Retention times were 3.9 min for [ 
Validation
Validation of analytical methods
In order to produce a radiopharmaceutical according to GMP regulations, QC with validated analytical methods is needed. Validation of compendial tests for osmolarity, residual solvents, endotoxins and sterility was conducted previously according to the respective compendial monographs, as applicable. However, the specific UPLC method for the QC of [
18 F]FB-IL2 needed to be validated. Additional file 1: Table S1 describes the different tests for the validation of the UPLC QC method and their corresponding acceptance criteria.
Validation of the production method
To assure that the production method is robust and results in a product with consistent quality, validation of the production method was performed. Validation of [
18 F]FB-IL2 consisted of four independent productions, including QC, as shown in the results section. All batch productions had to comply with the predefined specifications summarized in Table 2 . During validation the stability of [ 18 F]FB-IL2 has been investigated using UPLC analysis. Radiochemical purity was determined directly after labeling and 1 h after production.
Documentation
Documentation is an essential part in the development of a radiopharmaceutical produced according to GMP regulations and is needed to prove the overall quality of the final product (Patel & Chotai, 2011) . All methods are documented in Standard Operation Procedures (SOPs). Validation results of both analytical methods and the production method are documented in performance qualification (PQ) validation reports, which are authorized by a Qualified Person (QP). The Master Batch Record (MBR) is drafted to describe the general production process, including details on reagents, materials and equipment used, and specific step-by-step instructions for production. Test methods are provided with instructions for testing supplies, materials, products, and other production-related tasks and activities (Patel & Chotai, 2011 
Results
Technology transfer
Technology transfer describes the translation of methods developed in R&D setting to a GMP environment (Fig. 1) . This environment can potentially differ in terms of equipment, material and personnel. Moreover, production needs to be fully automated and performed in a closed and shielded hot cell. To avoid cross-contamination, synthesis modules with disposable cassettes are recommended over modules with fixed tubing (otherwise, thorough validation of washing procedures would be required) or manual or robotic methods. To ensure sterility of the final product the production needs to be performed in a classified cleanroom and hot cell, with the final filtration step in grade A in B. Additionally the final drug product needs to be of consistent predefined quality, stable and in a formulation suitable for clinical application. The initial transfer of the production of both F]SFB for the binding sites of IL2 (the primary amino group of lysine residues), resulting in low yields. Liquid chromatography-mass spectrometry (LC-MS) and UPLC were performed to characterize the impurity. These analyses showed that the impurity had a molecular weight (301 g/mol) equal to that of TSTU, which is used as a reagent in the [ 18 F]SFB synthesis. However, the retention time on UPLC was distinctly different from that of TSTU. We have not been able to elucidate the identity of the impurity. To improve separation of this unidentified impurity from [ to a class C cleanroom and a class C hot cell. There, the procedure started with the reformulation step using the Modular-Lab PharmTracer Eckert & Ziegler synthesis module. End formulation in~55% ethanol in water, diluted 1:10 with saline (ethanol < 10%) shortly before use.
Final formulation adapted for patient use: 9% ethanol, 4.5% glucose, 0.5% HSA, 0.1% SDS and 0.0001% phosphoric acid. An excipient in the final formulation occasionally precipitated.
Precipitation of HSA at low pH (< 4). Amount of phosphoric acid at washing/elution step adapted (100 times diluted).
Part 2 -[ 18 F]FB-IL2
Another cause for low yields during the conjugation reaction was the instability of IL2. At room temperature, IL2 has the tendency to aggregate after reconstitution in water. Moreover, at higher temperatures (> 60°C) the protein rapidly denatures (Di Gialleonardo et al., 2012b) . During preclinical development, the protein solution was therefore collected from storage just before the start of the production and kept at − 10°C until the start of the reaction with [ 18 F]SFB. For preclinical studies, the reconstituted IL2 could be added manually shortly before the conjugation reaction. However, this was not an option for the clinical production, since the production was performed with an automated synthesis module in a closed hot cell. A reagent vial with the protein solution already had to be connected to the cassette in the synthesis module at the start of the [ 18 F]SFB synthesis. Since the IL-2 solution was not cooled, this resulted in aggregation of the protein in the warm hot cell (approximately 2 h at > 30°C). An external cooling device was therefore implemented to keep the IL2 reagent vial cold. Unfortunately, this did not result in a higher yield. A possible explanation for this disappointing result was that during transport via tubing from the external cooling device to the reaction vial IL2 adsorbed to the long disposable polyethylene tubing and valves. As for the conjugation reaction only 200 μL of IL2 solution is used, a relatively large fraction of the solution was adsorbed to the long tubing. To overcome this problem, the IL2 solution was added directly to the reaction vial, which was cooled at − 10°C in a Peltier heating and cooling system until the start of the conjugation reaction. Just before the [ 18 F]SFB solution was transferred to this reaction vial, the temperature of the oven was increased to the reaction temperature of 50°C.
Another critical parameter in the conjugation was the narrow pH range of the reaction mixture required for the conjugation reaction. Previously the conjugation reaction was performed in borate buffer pH 8.3. We found higher yields in a borate buffer pH 8.5. Higher pH values (> 8.5) led to faster hydrolysis of [
18 F]SFB, reducing the amount of SFB available for conjugation to IL2. And at lower pH values, a larger fraction of the amino groups of the lysine residues of the protein is protonated and thus not readily available for the reaction with [ 18 F]SFB.
As mentioned above, IL2 has the tendency to aggregate and to adhere to tubing, valves, HPLC columns and sterilization filters. As a result, the recovery of [
18 F]FB-IL2 from the HPLC system was poor. Therefore, the HPLC method was replaced by a solid-phase extraction using a tC2 Sep-Pak cartridge. With this method the surface area for the protein to adhere to is lower, resulting in a higher recovery. This method has previously been used for the purification of Thereafter, [ 18 F]FB-IL2 was washed from the column with a more apolar eluent (acidified 100% ethanol), thereby also reducing adsorption to tubing and valves. When using the standard low protein binding sterilization filters (diameter 33 mm), still approximately 50% of the radiolabeled product adsorbed to the filter. When filters with a smaller diameter size (diameter 13 mm) were used, the amount of protein that adsorbed to the filter was substantially reduced to 25%. To further prevent aggregation and adsorption, HSA, glucose and SDS were added to the final formulation. The pH of this final formulation was critical, as we occasionally Veen et al. EJNMMI Radiopharmacy and Chemistry (2019) observed precipitation of a white substance in the product vial. This precipitation was reversible and appeared to be pH dependent as it dissolved again by increasing the pH using sodium hydroxide (NaOH). Therefore, the concentration of H 3 PO 4 , which was used during elution of the tC2 Sep-Pak cartridge, was reduced from 5 μL 25% H 3 PO 4 in 1 mL ethanol to 5 μL 0.25% H 3 PO 4 in 1 mL ethanol and by an additional washing of the cartridge with water for injection to remove residual acid from the cartridge, valves and tubing before elution of the product. The final formulation for patient use contains 9% ethanol, 4.5% glucose, 0.5% HSA, 0.1% SDS and 0.0001% H 3 PO 4.
Validation
Validation of analytical methods
All PQ test results for the UPLC method validation were within acceptance criteria (Additional file 1: Table S1 ). Some specific important issues for the analysis of [ 18 F]FB-IL2 using UPLC had to be taken into account. First, addition of HSA resulted in a large UV peak in the UPLC chromatogram. However, the resolution between HSA and other components is sufficient (> 1.5) to distinguish the HSA peak from the other components. Second, the protein IL2 could be detected at a wavelength of 280 nm. However, the UV absorption of some impurities at 280 nm was insufficient to be detected. These impurities could be adequately measured at 225 nm and therefore a dual wavelength detector, operated simultaneously at 225 and 280 nm, was used. Third, the maximum concentration of IL2 in the tracer solution is close to the detection limit. For conditioning of the UPLC column it was important to perform two runs with matrix (formulation buffer) before injection of the radioactive sample. Otherwise carry-over of impurities of previous runs could interfere with the analysis. Finally, radiolabeled IL2 is slightly more lipophilic than unconjugated IL2. A free amino group, which is protonated (and therefore positively charged) under physiological conditions, is converted into a neutral amide group after the conjugation reaction. This resulted in a delay in retention time of 0.6 to 1.0 min, as compared to naïve IL2.
Validation of the production method
Validation results are displayed in Table 2. [ 18 F]FB-IL2 could be produced with a consistent quality complying to all predefined specifications as described in Despite the low radiochemical yield, one production yields sufficient radiotracer for injection of one or two patients. Stability was investigated by measuring the radiochemical purity directly after labeling and 1 h after production. Table 3 shows that within 1 h the radiochemical purity did not decrease more than 0.3%. This was within the test-retest variability of the UPLC analysis method. Therefore, the expiration time is set at 1 h.
Documentation
As described in the methods section, all methods and the production process have been documented to ensure traceability of the production of Corresponds to a max dose of 50 μg (3 nmol) for a standard injection volume of 10 mL 
Discussion
The road to a radiopharmaceutical suitable for clinical studies can be challenging and time-consuming. Major barriers and unexpected problems might be encountered during the translation from a R&D to a GMP production method. Here we exemplify this road with the complex production method of [ 18 F]FB-IL2, the first-in-human fluor-18 labeled IL2 tracer for use in clinical studies to image activated T-cells. This radiopharmaceutical can now be produced consistently, although still in relatively low yields, sufficient for one or two patients. The final product meets the strict GMP requirements and is safe to use in clinical studies. We hope the description of this complex translation, including IMDP, contributes to a faster development of other new interesting radiopharmaceuticals.
There is a great interest in molecular imaging of activated T-cells. To further improve the production of this promising radiopharmaceutical the potential causes for the still relatively low yields have to be further investigated in the future. During synthesis, small volumes were being transported via relatively long tubing. This could lead to a loss of tracer, especially since IL2 has the tendency to adhere to tubing. Moreover, only a very low amount of protein was used, as IL2 has already pharmacological effects at a low concentration. Finally, during purification with the tC2 cartridge, part of the radiolabeled IL2 might have been washed away with the 50% aqueous ethanol solution. 
